Pfizer

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

FDA · non-small cell lung cancer · 5 min

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.

Otsuka Voyxact Data and Pfizer AI Deal Tracker

IgA nephropathy · 8 min

Drug & pharma latest press release traffic this week clustered on two files: Otsuka’s Voyxact (sibeprenlimab-szsi) kidney-function data in IgA nephropathy, and Pfizer’s license deal with Chai Discovery for generative AI drug design. Here is the BD-relevant readout without the rumor layer.

China: The Innovation Factor – Implications for Pharma BD and Investors

6 min

China has emerged as a global innovation powerhouse, now leading in 37 of 44 critical technologies. This article examines what this means for pharmaceutical deal-making, investment decisions, and competitive strategy for BD teams and executives.

Pfizer sharpens prostate cancer case with Talzenna win — oncology

oncology · 5 min

Pfizer announced a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer, setting up a potential broader label. This analysis covers the TALAPRO-3 results, implications for the prostate cancer treatment landscape, and key milestones for pharma teams and investors.

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

ASCO · oncology · 8 min

Structured plan for ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come